MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in ... How Healthy Stem Cells Turn Into Or ...

A novel acoustofluidics method enhances intracellular nanoparticle delivery, improving biophysical research and therapeutic ...

2025 — Scientists have developed an innovative solar-powered method to transform sewage sludge -- a by-product of wastewater treatment -- into green hydrogen for clean energy and single-cell ...

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle ...

MaxCyte (NASDAQ:MXCT – Free Report) had its price objective cut by Stifel Nicolaus from $11.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on ...

Investment analysts at William Blair issued their Q1 2026 earnings estimates for MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will ...

TG Therapeutics to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, its allogeneic CD19 CAR T cell therapy ...

You can increase white blood cells (WBCs) by taking certain medications and eating immune-boosting foods, like yogurt, lean protein foods, antioxidant-rich vegetables, and more. Maintaining a normal ...

PLYMOUTH MEETING, PA, USA I March 13, 2025 I INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help ...